Welcome to LookChem.com Sign In|Join Free

CAS

  • or

219685-50-4

Post Buying Request

219685-50-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Immunoglobulin,anti-(human complement C5 a-chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide withhuman-mouse monoclonal 5G1.1 light chain, dimer (9CI) 219685-50-4

    Cas No: 219685-50-4

  • No Data

  • 1 Kilogram

  • 10000 Metric Ton/Month

  • Shanghai Upbio Tech Co.,Ltd
  • Contact Supplier
  • Immunoglobulin,anti-(human complement C5 a-chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide withhuman-mouse monoclonal 5G1.1 light chain, dimer (9CI)

    Cas No: 219685-50-4

  • No Data

  • 1 Kilogram

  • 1 Metric Ton/Day

  • Shandong Hanjiang Chemical Co., Ltd.
  • Contact Supplier
  • Immunoglobulin,anti-(human complement C5 a-chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide withhuman-mouse monoclonal 5G1.1 light chain, dimer (9CI)

    Cas No: 219685-50-4

  • No Data

  • 1 Kilogram

  • 1 Metric Ton/Month

  • HANGZHOU YUNUO CHEMICAL CO.,LTD
  • Contact Supplier

219685-50-4 Usage

Description

Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC50 = 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9.Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).

Originator

Alexion (US)

Uses

Treatment of autoimmune disease such as rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis, and autoimmune hemolytic anemias.

Brand name

Soliris

General Description

Eculizumab (Soliris) is a monoclonal antibodythat binds to the terminal complement protein C5 inRBCs. This blocks the cleavage of C5 and halts the processof complement-mediated cell destruction of the RBCs.Eculizumab has been shown to be effective in treating PNHand in March 2007 was approved by the FDA for treatingPNH.

Clinical Use

Recombinant monoclonal antibody:Paroxysmal nocturnal haemoglobinuria (PNH)Atypical haemolytic uraemic syndrome (aHUS)Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (MG)

Metabolism

Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Check Digit Verification of cas no

The CAS Registry Mumber 219685-50-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,9,6,8 and 5 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 219685-50:
(8*2)+(7*1)+(6*9)+(5*6)+(4*8)+(3*5)+(2*5)+(1*0)=164
164 % 10 = 4
So 219685-50-4 is a valid CAS Registry Number.

219685-50-4Upstream product

219685-50-4Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 219685-50-4